1206163-59-8

Basic information

• Product Name: N-(5-(4-(bromomethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
• Synonyms: N-(5-(4-(bromomethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
• CAS NO: 1206163-59-8
• Molecular Formula: C₁₇H₁₅BrN₄O
• Molecular Weight: 371.2312
• Mol File: 1206163-59-8.mol

Chemical Properties

• Appearance: /
• Density: 1.63±0.1 g/cm3(Predicted)
• PKA: 8.00±0.20(Predicted)
• CAS DataBase Reference: N-(5-(4-(bromomethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-(4-(bromomethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide(1206163-59-8)
• EPA Substance Registry System: N-(5-(4-(bromomethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide(1206163-59-8)

Safety Data

• Hazardous Substances Data: 1206163-59-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
BPTU is utilized as a key component in the development of new drugs due to its ability to modulate specific biological targets. Its unique molecular structure allows it to potentially address a range of therapeutic areas, making it a promising candidate for creating innovative pharmaceuticals.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, BPTU serves as a subject of study for understanding its interactions with biological systems. Researchers are interested in its potential to bind to and affect the activity of certain proteins or enzymes, which could lead to the discovery of new therapeutic agents or mechanisms of action.
Used in Drug Design and Optimization:
BPTU is employed in the process of drug design and optimization, where its molecular structure is analyzed and modified to improve its pharmacological properties, such as potency, selectivity, and bioavailability. This process is crucial for transforming a promising chemical compound into a viable drug candidate.
Used in Target Identification and Validation:
BPTU is used as a tool in target identification and validation studies. By observing how it interacts with various biological targets, researchers can gain insights into the mechanisms of disease and potential points of intervention, which is fundamental in the development of targeted therapies.

Upstream product

• 1142936-49-9 cyclopropanecarboxylic acid [5-(4-hydroxymethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-amide 
• 19798-81-3 2-Amino-6-bromopyridine 
• 1010120-59-8 ethyl N-[(6-bromopyridin-2-yl)carbamothioyl]carbamate 
• 1010120-55-4 5-Bromo-[1,2,4]Triazolo[1,5-a]pyridine-2-ylamine 
• 1142943-96-1 cyclopropanecarboxylic acid (5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-amide 
• 1142936-90-0 N-[5-(4-methylphenyl)-[1,2,4]trithiazole[1,5-a]pyridin-2-yl]cyclopropanecarboxamide 
• 5720-05-8 4-methylphenylboronic acid 

Downstream Products

• 1206161-97-8 N-(5-{4-[(1,1-dioxo-1λ⁶-thiomorpholin-4-yl)methyl]phenyl}-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide 

Relevant articles and documents

NOVEL PROCESS FOR THE PREPARATION OF FILGOTINIB AND INTERMEDIATES THEREOF

The present invention relates to a novel process for the preparation of filgotinib or a pharmaceutically acceptable salt and intermediates thereof which avoid Suzuki coupling reaction. (I)

Synthesis method of JAK1 inhibitor Filgotinib

The invention provides a preparing method of Filgotinib. The preparing method comprises the following steps that (1), 2-amino-6-bromopyridine reacts with a p-methylbenzene derivative to prepare a compound 1; (2), the compound 1 reacts with ethoxycarbonyl

[1,2,4]triazol[1,5-a]pyridine compound as well as preparation method and medical application thereof

The invention relates to a [1,2,4]triazol[1,5-a] pyridine compound as well as a preparation method and medical application thereof. Particularly, the invention relates to the compound shown in a general formula I, the preparation method of the compound, a

METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS

The present invention discloses compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, or a solvate or the salt of a solvate thereof, pharmaceutical compositions comprising the same, and methods of treatment using the same, for

PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

The present invention discloses pharmaceutical compositions comprising: a compound according to Formula I: useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, d

NOVEL SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS

The present invention discloses salts of a Compound 1: useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of

FILGOTINIB: Tyrosine-protein kinase JAK1 inhibitor, treatment of rheumatoid arthritis, treatment of crohn's disease

Rheumatoid arthritis (RA), a chronic autoimmune inflammatory disease, is associated with pain, progressive disability, systemic comorbidities and early death. Filgotinib (GLPG-0634), a new selective tyrosine-protein kinase (JAK1) inhibitor, is currently i

NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

A novel compound able to inhibit JAK is disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting exa